Equity Profile

VCYT

VERACYTE INC

Health CareBiotechnology$3.9B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Veracyte Inc (VCYT) is a biotechnology company that focuses on improving patient care through genomic diagnostics. Their innovative tests help physicians make more informed decisions in cancer diagnosis and treatment, which is increasingly important in the evolving healthcare landscape.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, and investors will be looking for continued strong performance.

$0.52

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will signal the company's ability to expand its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1 2026, Veracyte reported an EPS of $0.52, significantly beating expectations by 126%. However, the stock experienced a slight decline of 1.43% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing customer engagement.
Plans to invest in research and development for new diagnostic tests.

Expectations

Wall Street Expectations

Overall expectations for Veracyte's upcoming earnings are cautiously optimistic, given their strong track record of beating EPS estimates.

Bull Case

If Veracyte continues to deliver strong EPS growth and shows signs of revenue expansion, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet or provide guidance on revenue growth, it could raise concerns about its future prospects and negatively impact the stock.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.52

EPS is a key indicator of the company's profitability and growth potential, and investors will be looking for continued strong performance.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will signal the company's ability to expand its market presence and product adoption.

Gross Margin

N/A

Gross margin will provide insight into the company's cost management and pricing strategy, which is crucial for maintaining profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Investors will closely monitor revenue growth as it indicates the company's ability to scale its operations and capture market share.

How will management address the recent fluctuations in stock performance post-earnings?

Understanding management's perspective on stock volatility could provide insights into their confidence in future growth and operational strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to leverage its recent product innovations to drive revenue growth, which could lead to a significant upside surprise.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Insider buying activity suggests confidence in the company's future prospects.

Key Risk

If revenue growth comes in below 5%, it could undermine the bullish narrative surrounding the company's expansion efforts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Veracyte can maintain its impressive EPS growth while also expanding revenue.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm the bull case, indicating strong market demand for Veracyte's products.

Bear Confirmed If

Conversely, if revenue growth is below 5%, it would raise serious concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations and raises guidance, history suggests the stock could see an average one-day move of +0.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management remains cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential downside move, with an average decline of 1.71% based on past performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive positioning in the diagnostics market.
3Details on customer acquisition strategies and engagement metrics.
4Insights into research and development progress for future tests.
5Any guidance on future earnings expectations or market conditions.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and growth potential, and investors will be looking for continued strong performance.

$0.52

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will signal the company's ability to expand its market presence and product adoption.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

VCYT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+367.92%

Avg Stock Reaction

+0.09%

Last Quarter Recap

In Q1 2026, Veracyte reported an EPS of $0.52, significantly beating expectations by 126%. However, the stock experienced a slight decline of 1.43% the following day.

Management Promises & Guidance

Continued focus on expanding product offerings.
Commitment to enhancing customer engagement.
Plans to invest in research and development for new diagnostic tests.

Expectations

Wall Street Expectations

Overall expectations for Veracyte's upcoming earnings are cautiously optimistic, given their strong track record of beating EPS estimates.

Bull Case

If Veracyte continues to deliver strong EPS growth and shows signs of revenue expansion, it could lead to increased investor confidence and a higher stock price.

Bear Case

Conversely, if the company fails to meet or provide guidance on revenue growth, it could raise concerns about its future prospects and negatively impact the stock.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.52

EPS is a key indicator of the company's profitability and growth potential, and investors will be looking for continued strong performance.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will signal the company's ability to expand its market presence and product adoption.

Gross Margin

N/A

Gross margin will provide insight into the company's cost management and pricing strategy, which is crucial for maintaining profitability.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will be the reported revenue growth rate for the quarter?

Investors will closely monitor revenue growth as it indicates the company's ability to scale its operations and capture market share.

How will management address the recent fluctuations in stock performance post-earnings?

Understanding management's perspective on stock volatility could provide insights into their confidence in future growth and operational strategies.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Veracyte's ability to leverage its recent product innovations to drive revenue growth, which could lead to a significant upside surprise.

Supporting Evidence

Veracyte has consistently beaten EPS estimates, suggesting strong operational execution.

The options market is pricing a larger move than historical averages, indicating heightened expectations.

Insider buying activity suggests confidence in the company's future prospects.

Key Risk

If revenue growth comes in below 5%, it could undermine the bullish narrative surrounding the company's expansion efforts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Veracyte can maintain its impressive EPS growth while also expanding revenue.

Bull Confirmed If

A revenue growth rate exceeding 15% would confirm the bull case, indicating strong market demand for Veracyte's products.

Bear Confirmed If

Conversely, if revenue growth is below 5%, it would raise serious concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±17.32%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.

Options are pricing ±17.3% while VCYT has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

80.2%

Calls (4K)P/C Ratio: 0.00Puts (600)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Veracyte beats expectations and raises guidance, history suggests the stock could see an average one-day move of +0.09%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations but management remains cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

Should the company miss expectations, history indicates a potential downside move, with an average decline of 1.71% based on past performance.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·0 sells

Members

House only

Est. Notional

$2,002.00–$30,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive positioning in the diagnostics market.
3Details on customer acquisition strategies and engagement metrics.
4Insights into research and development progress for future tests.
5Any guidance on future earnings expectations or market conditions.